Dompe U.S.
3 articles with Dompe U.S.
-
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
-
Dompé announces first treatment with Oxervate™ eye drops (cenegermin-bkbj), for neurotrophic keratitis (NK)
1/3/2019
Now available through Accredo, Oxervate is the first-in-class recombinant human nerve growth factor (rhNGF) and holds the potential to completely heal NK.
-
Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis
8/23/2018
Oxervate is the first-ever application of a human nerve growth factor as drug or treatment, and is the first-ever topical biologic medication approved in ophthalmology.